|
|
Article: Gilead Sciences Makes VISTIDE Available in France Through an ATU for the Treatment of Relapsing CMV Retinitis.
- Article from:
- Business Wire
- Article date:
- March 12, 1996
CopyrightCOPYRIGHT 1996 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FOSTER CITY, Calif.--(HealthWire)--March 12, 1996--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has made VISTIDE(R) (cidofovir intravenous) available in France for use under an ATU Program for the treatment of relapsing cytomegalovirus (CMV) retinitis in patients with AIDS.
The ATU (Autorisations Temporaires d'Utilisation) nominative procedure is a temporary authorization from the French Agence du Medicament (FMA) that will make VISTIDE treatment available to patients with relapsing CMV retinitis who have failed currently available intravenous treatments. The FMA will determine eligibility on a patient-by-patient basis, and Gilead will provide the ...